At the University of Southern California, I built a 20-year Markov model comparing tirzepatide with semaglutide in obesity, returning $97,723 per QALY. I also assessed a published health technology assessment, identifying methodological weaknesses and translating the findings into an evidence-generation and pricing strategy.
My research includes interviewing a practicing cardiologist about adoption of a newly launched oral therapy and co-authoring a manuscript on cardiovascular disease burden across 31 Chinese provinces. At Airdoc Technology, I interpreted a clinical imaging dataset alongside a senior engineer, raising model area under the curve from 0.65 to 0.92. I’m completing a Master of Science in Healthcare Decision Analysis at the University of Southern California.
